Brane's Brain R&D Spun Out, Seeks Funding
This article was originally published in Start Up
Executive Summary
Nikem spun out its R&D assets with about a years' worth of funds to pursue development of its neuropathic pain and Parkinson's disease compounds, which are currently in preclinical development. The company, Brane, is seeking Series A funding.